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Thrombin is a critical enzyme involved in blood coagulation and haemostasis. For 
this reason the study of its interactions with substrates, inhibitors and modulator is 
essential. It is also a unique enzyme in the serine protease family because unlike enzymes 
like trypsin and chymotrypsin its activity is modulated by various endogenous and 
exogenous ligands. This is due to the presence of “exosites” on the thrombin surface. 
Exosite II, unlike exosite-I, has not been characterized for its allosteric effect. In order to 
understand the structural basis of interaction and inhibition of inhibitor 4AS, which 
possibly interacts with exosite-II, native bovine thrombin crystals and human thrombin 
   
 xi 
crystals grown in presence of 4-AS were prepared. X-ray diffraction data was collected on 
4AS soaks of native bovine thrombin as well as human thrombin crystals. The data were 
phased by molecular replacement using appropriate search models. The structures were 
refined to R factors of 0.24 and 0.27 for native bovine thrombin-4AS soaks and human 
thrombin-4AS co-crystals respectively. Examination of a 2Fo-Fc
 
 electron density map 
revealed no density for 4-AS. Low affinity of the inhibitor may be the reason for its 
absence in the solved structures. In the process of solving these structures, unliganded 
native bovine thrombin in a new crystal form, previously unreported in literature, was 
solved. The structure shows an overall topology similar to that found in previously 
published thrombin molecules. Examination of the crystal packing shows that the exosite-
II is solvent exposed. This crystal form can be used in the future to study interaction of 
exosite-II ligands. 
To characterize the interaction of sucrose octasulfate with thrombin, which may 
interact with thrombin exosite-II, fluorimetric equilibrium binding titrations were 
performed using the active site fluorescent probe para-amino benzamidine. At 
physiological salt concentrations, the KD was found to be ~22 μM, which is lower than 
heparin fragment of corresponding length. The higher affinity was attributed to the high 
charge density of the ligand. Measurement of KD at different salt concentrations showed a 
significant amount of contribution to the binding energy from ionic interactions. Based on 
the salt dependence experiments, the number of charged interactions per sucrose 
octasulfate molecule interacting with thrombin was found to be 3.5. Competitive 
   
 xii 
experiments of sucrose octasulfate with FDs (a sulfated dehydro-polymer being 
investigated in the lab for its anticoagulant properties) for inhibition of thrombin activity 
showed competitive effects that did not appear to follow Dixon-Webb competitive 
phenomenon. It was found that sucrose octasulfate itself is a weak inhibitor of thrombin. 
To investigate the mode of interaction, co-crystals of sucrose-ocasulfate complexed with 
thrombin were prepared. High resolution data (2.2 Å) was collected. The structure solved 
using this data showed weak density for two sucrose octasulfate molecules. Sucrose 
octasulfate was modeled into this density and refined. The refined structure shows that two 
sucrose octasulfate molecules bind to two thrombin monomers of the asymmetric unit at 
exosite-II. One of the sucrose octasulfate molecules interacts with both monomers, and 
could be present as an artifact of crystal packing. The second molecule interacts with 
exosite-II of only one of the thrombin monomers. The key residues involved in the 
interaction are Lys236, His91, Arg93 and Arg101. 
The thrombin-sucrose octasulfate structure does not show any major deviation from 
unliganded structure. It is possible that the conformational change may have been masked 
due to crystal packing. Characterization of this novel interaction mode of sucrose 
octasulfate interaction with thrombin adds one more candidate to the list of compounds 
that interact with exosite-II in a manner very similar to heparin, but unlike heparin can 
inhibit thrombin activity. 
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CHAPTER 1 INTRODUCTION  
 
 
1.1 Physiological Role of Thrombin 
Thrombin (fIIa) is the ultimate trypsin-like serine protease produced as a result of 
upstream activation of blood coagulation cascade. Vascular injury triggers this cascade, 
which is now understood to be brought about by two convergent pathways: intrinsic 
pathway and extrinsic pathway.1, 2 Both pathways converge to generate fXa, which 
complexes with factor Va (fVa), tissue factor (TF) and calcium on platelet cell. surface to 
form the prothrombinase complex.3-7 This major complex catalyzes the formation of 
thrombin from its zymogen, prothrombin (fII).8 fII is biosynthesized in liver in a Vitamin 
K dependent manner.9-15
Thrombin serves pivotal function in hemostatis, thrombosis and cell 
differentiation (Figure 1).
 
16-19 In a sodium-dependent manner, thrombin catalyzes the 
conversion of fibrinogen to fibrin monomers.20 The fibrin monomers so formed rapidly 
polymerizes to form a clot, which is stabilized by covalent cross-linking of lysine and 
glutamine residues through a reaction catalyzed by transglutaminase action of factor 
XIIIa (fXIIIa).  
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Thrombin also activates a metal-dependent carboxypeptidase, thrombin-activable 
fibrinolysis inhibitor (TAFI) to TAFIa.21-23 TAFIa removes lysine residues recognized by 
fibrinolytic enzymes from cross-linked fibrin clot. In addition to the above stated direct 
pro-coagulant actions, thrombin can also activate factors V, VII and VIII, in effect 
enhancing its own production.5, 24-28 A group of receptors on platelets called proteinase-
activated receptors (PARs) 1, 3 and 4 have been identified, which are proteolytically 
activated by thrombin. This activation has been reported to cause platelet aggregation, 
degranulation and surface expression of procoagulant phospholipids.29-32 The activation 
of PARs is significantly enhanced by surface glycoproteins GPIbα.33 In contrast to its 
pro-coagulant activities, the presence of thrombomodulin (TM), an integral membrane 
protein in intact vascular endothelium, converts thrombin into an anti-coagulant, which 
can activate protein C (PC). Activated protein C proteolytically deactivates factor VIIIa 
(fVIIIa) and fVa. TM is an integral membrane protein in intact vascular endothelium. The 
anticoagulant property of thrombin in presence of TM ensures that there is no undue 
formation of thrombus.34, 35 
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Figure 1. Role of thrombin in blood coagulation. Procoagulant and anticoagulant actions 
of thrombin are shown in red and green lines respectively. Cofactors (if any) for the 
reactions are written in blue above the lines. Bold lines and arrows show conversion.red 
(\) sign indicates inhibition and (+) indicates potentiation. 
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Thrombin activity is regulated by irreversible serine proteinase inhibitors 
(SERPINS) antithrombin-III (ATIII) in blood and heparin cofactor (HCII) in extra-
vascular tissue. Their activity is greatly enhanced by sulfated glycosaminoglycans 
(GAGs) heparin sulfate and heparan sulfate.36-38
1.2 Overview of Thrombin Structure 
 
Thrombin (EC 3.4.21.5, MEROPS classification peptidase S01.217 of family 
S1A, clan PA(S)39) is a serine protease belonging to the trypsin family. Like trypsin, it 
employs the same chemical mechanism for proteolysis. However, in contrast to trypsin, 
thrombin is highly selective for its substrate and its activity can be modulated by 
cofactors and inhibitors. This property can be attributed to the presence of a series of 
insertion loops which bind to cofactors and inhibitors. Thrombin and other serine 
proteases like trypsin, chymotrypsin, plasmin and kalikrein have evolved to perform 
specialized functions from the same ancestral protein through divergent evolution.40-42
The formation of thrombin from prothrombin occurs by the cleavage of two 
peptide bonds viz. R320-I321 and R272-T273 (prothrombin numbering) due to the action 
of prothrombinase complex.
      
8 Kinetic studies suggest that there is no particular preference 
for the order in which these bonds are broken.43 The products of each of these cleavages 
are:  membrane-bound, catalytically-active, meizothrombin and catalytically inactive 
prethrombin + prothrombin fragment 1.2 respectively. There is an additional cleavage of 
R284-T285 in human prothrombin which does not occur in bovine prothrombin. 
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Figure 2: Activation of Prethrombin. Prethrombin (green) is superposed on 
thrombin(blue). Important changes associated with activation involve flipping of Ile-16 
and Asp194 to form a salt bridge and movement of Asp189, a residue important for 
determining substrate specificity. The model was taken from PDB (PDB ID 1MKX)44
 
 
and superposed using superpose utility of CCP4 0.6.2. The figure was generated using 
PyMol using PDB coordinates of 1MKX. 1MKX is a co-crystal structure of bovine 
thrombin and prethrombin. 
The cleavage of R320-I321 is critical for thrombin activation. Crystallographic 
analysis of structures of prethrombin and thrombin reveal that the cleavage of the 
arginine-isoleucine bond leads to an outside-in flipping of the new amino terminal 
isoleucine residue and reorientation of D194 (thrombin numbering45, 46) side chain, 
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enabling them to form a salt bridge (Figure 2). This leads to a conformational change 
making the active site functional and more accessible to the substrate.44, 47
The primary structure of thrombin consists of two polypeptide chains: a short L 
chain and a large H chain, covalently linked together by a single disulfide linkage 
(Figure 4). H chain resembles the trypsin domain and consists of two β-barrel motifs at 
the junction of which are the catalytic residues Ser195, His57 and Asp102 which form 
the charge relay system.
 
45 Although the L chain is not involved in any of the major 
interaction with substrate or inhibitor, its presence is important for the structural stability 
and functioning of the enzyme. This also explains why genetic mutations to important L 
chain residues cause severe bleeding disorders.48
Figure 4  and 5. Show the thrombin molecule in standard orientation.
 
45
The entrance to the active site is restricted by two large insertion loops. The first 
is a relatively flexible loop called the “149 loop/autolysis loop/γ loop”, named so for its 
observed ex-vivo autolysis.
 Thrombin 
is a globular protein with a roughly ellipsoid shape. The active site cleft passes 
equatorially, bisecting the two β-barrel motifs in a perpendicular fashion. At the centre of 
the cleft is the catalytic triad.  In contrast to trypsin, the extended nature of the cleft 
allows the specificity of the substrate to extend much beyond the P1 specificity position 
(see section 1. 1.3). 
49 The second is the rigid “60 loop”. This loop is highly 
conserved in thrombin of all vertebrate species and contains a rigid –YPPW- hairpin β-
turn (see Figure 3). 
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Figure 3. Primary sequence alignment of H chain(top to bottom): human thrombin, 
bovine thrombin  and bovine chymotrypsin. The alignment was performed using 
CLUSTAL-X. The coloring is based on the chemical nature of residue side chains. 
Conserved regions are indicated by (*), conserved regions with homologous mutations 
are indicated by (:) and semi-conserved regions are indicated by (.). 
 
An examination of electrostatic surface potentials of thrombin reveals the 
presence of a polarized surface charge distribution. Three contiguous surface patches, one 
of negative potential and two of positive potential, have been identified to be crucial in 
cofactor/inhibitor binding and substrate recognition. The first positively charged surface 
patch is convex in shape and extends from where the active site cleft levels off (Figure 5, 
lower right). This site makes additional interactions with fibrinogen when it binds to 
thrombin and hence is termed as “fibrinogen recognition exosite” or “anion-binding 
exosite-I”.50 The second, more strongly positively charged surface patch extends from the 
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intermediate portion of the C-terminus helix of the H chain (Figure 5, upper left). Due to 
its interaction with heparin this site is termed as “heparin binding site” or “anion-binding 
exosite II”.51 A third site which lies near to the S1 specificity pocket consists of a small 
positively charged cavity with many ordered water molecules. This site is known to bind 
to Na+ ion, which is an allosteric effector of thrombin. Upon binding it converts thrombin 
to a kinetically distinct form called “fast” form. The unbound form of thrombin is called 
“slow” form. This transitioning from slow to fast form and vice-versa has been shown to 
be important for regulation of anticoagulant and procoagulant functions of thrombin.52-57
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Figure 4. Stereo view of human α-thrombin shown in standard orientation (cartoon 
representation). Catalytic triad is shown in stick . The figure was created using 
PyMOL0.99. 
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Figure 5. Stereo view of human α-thrombin shown in standard orientation (Electrostatic 
surface representation). Catalytic triad is shown in stick representation (Hidden behind 
the 60 loop). Important loops are circled. 
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1.3 Active Site Interactions 
       
The center of the active site cleft contains the catalytic triad which divides the 
active site cleft into two parts.  The interaction of regions in these two halves with the 
substrate determines the substrate specificity. The regions are termed “specificity 
pockets”. The regions of the active site cleft that interact with the residues of the substrate 
before the scissile bond are indicated as S1, S2, S3…Sn, S1  being the region that 
interacts with the residue immediately preceding the scissile bond. The corresponding 
residues of the substrates are indicated by P1, P2, P3,….,Pn. The regions of the active site 
cleft that interact with the residues of the substrate after the scissile bond are indicated as 
S1’,S2’,S3’,…,Sn’; S1’ being the region that interacts with the residue immediately after 
the scissile bond. The corresponding residues of the substrate are indicated by 
P1’,P2’,P3’,…,Pn’ (see Figure 6).  (Note that Pn to Pn’ are by definition contiguous in 
primary sense in N-terminal to C-terminal direction.) 
O
N
H
Px
Px'
Sx'
Sx
 
Figure 6. Schechter and Berger nomenclature of specificity regions in substrate (P) and 
their corresponding specificity pockets in the active site cleft (S) around the scissile 
peptide bond (CO-NH). 
 
Scissile bond 
Pn            P1 
Sn            S1 
P1’            Pn’ 
S1’            Sn’ 
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Like trypsin, the S1 pocket in thrombin (Figure 7) contains acidic residue Asp189 
(thrombin numbering)* at its bottom. Due to this there is a strong preference for basic P1 
residue like arginine for binding in this site. However, unlike trypsin, the pocket in 
thrombin contains the less bulky residue Ala190. This allows accommodation of more 
hydrophobic/uncharged P1 groups. At the entrance to S1 pocket there is an acidic residue 
Glu192, which is important in determining specificity of substrate and inhibitor.45, 58-60
The S1’ pocket is limited in size by Lys60f residue of the 60 loop and can only 
accept P1’ residues with small polar side chains. The S2’ region is made up of less bulky; 
hydrophobic residues and hence can accept P2’ residues with bulky and hydrophobic side 
chains. S3’ region is wide, slightly acidic and prefers basic P3’ residues. 
 
On the top of the S1 binding pocket extends a hydrophobic region, the base of which is 
formed by Trp215 indole moiety. This region is subdivided into S2 cavity and the aryl 
binding S4 groove. 
1.3.1 PPACK-thrombin Interaction  
PPACK (D-Phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone) is an 
irreversible covalent inhibitor of thrombin.61
*Footnote: The thrombin numbering system is based on topological equivalence 
of residues to chymotrypsin residues. 
 Its crystal structure illustrates the role of 
specificity pockets in binding peptidyl substrates (Figure 8). The three residue peptidyl 
moiety of PPACK fits snugly in the active site pocket; making three hydrogen bonds with 
the extended thrombin segment Ser214 to Glu217 in a twisted anti-parallel manner.  
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The C-terminal P1-R carbonyl group covalently links to Ser195 Oγ and His57 
Nε2 via the tetrahedral hemiketal and methylene group. The side chain of the P1-R group 
fits into the S1 specificity pocket, forming a charged hydrogen bond with Asp189, 
Gly219 and a buried water molecule. The P2-Pro of PPACK fits into S2 cavity. The 
benzyl side chain of D-Phe moiety extends into the wide S4 aryl-binding site. With 
natural substrates, this site is occupied by P4 L-amino acyl side chain. The P3 side chain 
for substrates usually points away from the active site cleft. By comparing various 
substrates sequences that interact with the active site cleft, an optimal consensus 
sequence of FXPRSFR corresponding to P4 P3 P2 P1 P1’ P2’ P3’, has been deduced 
(Table 1).62-67 This sequence has been extremely useful for designing active site directed 
reversible inhibitors. As seen in Table 1 some substrates do not make optimal 
interactions with the active site. These substrates usually utilize additional binding sites 
distant from the active site cleft viz. Na+ binding site, anion-binding exosite-I or anion 
binding exosite-II. 
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Figure 7. Interaction of PPACK with human α-thrombin. P1-Arg-CH2, P2-Pro, P4-Phe 
and the catalytic triad (hidden behind the 60 loop) are shown in stick representation. 
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Table 1. Substrate sequences interacting with the active site of thrombin. The scissile 
bond is indicated by (    ). This figure was modified from Reference 17. 
                 
                                               
 
 
 
 
 
 
 
 
 
 
Substrate  P3 P4  P2 P1 P1’P2’P3’ 
Fibrinogen Aα 
 
Fibrinogen Bβ 
Factor V 
Factor V 
Factor V 
Factor VIII 
Factor VIII 
Factor XI 
Factor XIII 
PAR 1 
Protein C 
TAFI 
AT III 
HC II 
Consensus sequence 
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1.4 Interactions of Anion-binding Exosite I 
Exosite I is a surface depression which starts at the end of the P’ side of the active 
site cleft approximately 20 Å away from the catalytic triad. It is mainly formed by 
insertion loops 70 to 80 (equivalent to the calcium binding loop of trypsin but the Ca2+ 
ion replaced by Lys70 amine group68) with some bordering residues from 37 loop and 
Lys-109, Lys-110 side chains. The base of this depression is formed by the exposed 
hydrophobic side chains of Tyr-76 and Ile-82 which is surrounded by cationic side chains 
of lysines : 149E, 36, 109, 110, 81 and 70, and arginines 77A, 75, 67, and 73 (see Figure 
8).45, 68, 69 Exosite I is known to interact with fibrinogen, PARs, fV, fVIII, fXI, HCII, 
hirudin, TM and staphylocoagulase. 32, 70, 71
1.4.1 Thrombin-Hirudin Interaction: A Prototypic Exosite I interaction 
 
Hirudin is a 65 amino acid protein which was discovered in salivary secretions of 
European leech Hirudo medicinalis.72, 73 It is one of the most potent and selective 
thrombin inhibitor with a KD in femto-molar range. Since it was one of the first thrombin 
inhibitor investigated for binding to both exosite-I and the active site, it became a model 
for interaction of thrombin with thrombomodulin, PARs and fibrinogen. 
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Figure 8. Electrostatic potential surface of thrombin centered on anion-binding exosite-I. 
mportant residues comprising the exosite are labeled and shown in stick representation. 
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The crystal structure of thrombin-hirudin complex shows that the C-terminal 
domain of the inhibitor interacts extensively with exosite I by both hydrophobic and 
electrostatic interactions, accounting for high specificity of the inhibitor.74, 75 The N-
terminal domain binds to the active site, making several non-polar contacts in the active 
site cleft.76, 77 Mutagenesis studies by Stone et. al. show that substitution of acidic 
residues on the C-terminal domain reduces the association rate of complex formation and 
decrease the affinity. A similar lowering of affinity is observed when hydrophobic 
residues are substituted.78
Comparison of the NMR structure of free hirudin with the thrombin bound form 
shows that in free form the N-terminal end of hirudin is disordered, and upon binding to 
thrombin adopts a 3
 
10-helical form.74, 79, 80 This gives rise to a large change in heat 
capacity. An unusually large change in heat capacity and an entropy deficit associated 
with the formation of an ordered structure when hirudin binds to thrombin suggests an 
induced-fit mechanism of binding. This mechanism has been supported by kinetic 
studies.81, 82
1.5 Interactions of Anion-binding Exosite-II 
 A binding model based on initial recognition by electrostatic steering by 
complementary charged interactions followed by change in inhibitor structure to make 
optimum hydrophobic interaction has been proposed. 
The mapping of heparin binding exosite-II was done using a combination of site-
directed mutagenesis and functional studies of heparin induced AT-III inhibition of 
thrombin. Exosite-II covers an area of approximately 200 Å2. (upper left corner of 
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Figure5) It is located near the C-terminus of the H-chain of thrombin, centered on the 
groove formed by Leu234 and surrounded by basic side-chains of Arg93, Arg101, 
Arg165, Arg233, Arg126, Lys236, Lys235, Lys240 and His91. (see Figure 9) The 
charges of most of these basic residues are not compensated by acid residues and 
therefore exosite-II has the highest charge density on the thrombin surface. The kringle-2 
domain of prothrombin forms a non-covalent adduct with exosite-II, indicating that it is 
not solvent exposed in the zymogen. 
Besides heparin, many ligands interacting with exosite-II have been identified. 
Platelet receptor GpIbα, which acts as a cofactor for activation of PARs, interacts with 
thrombin utilizing exosite-II. Prothrombin fragment 1.2, CS moiety of TM and fVIII 
interact with thrombin via exosite-II. Many exogenous natural inhibitors like Haemadin 
form Haemadipsa sylvestris leech, interacts with thrombin via exosite II and the active 
site. Due to their polyanionic nature, many DNA and RNA aptamers have been designed 
to interact with exosite-II.83, 84  Recently, Suramin was shown to inhibit thrombin by 
binding to exosite-II.85
1.5.1 Thrombin-heparin interaction 
  
Naturally occurring heparin is a sulfated GAG composed of repeating iduronic 
acid and N-acetyl glucosamine units with variable sulfation pattern and chain length. As a 
result heparin is inherently polydisperse. It is primarily composed of a major (~75-95%) 
trisulfated disaccharide repeating unit consisting of 2-O-sulfo-α-L-iduronic acid 1→4 
linked to 6-O-sulfo-N-sulfo-α-D-glucosamine (→4]IdoA2S(1→4)GlcNS6S[1→) along 
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Figure 9. Stereoview of anion binding exosite-II represented by semi-transparent 
electrostatic surface. Red and blue indicate electropositive and electronegative regions 
respectively. Important residues are labeled and represented in stick overlaid with semi-
transparent electrostatic surface. 
 
 
21 
 
 
Figure 10. The structures of the major (A) and minor (B) repeating sequences of heparin. 
X = SO3- or H and Y = SO3-
 
 or COCH3. 
with a number of additional minor disaccharide structures corresponding to its variable 
sequence (Figure 10). There is a unique sequence combination that makes specific 
interaction with AT-III, called the pentasaccharide sequence. It is composed of 
GlcNAc/NS6S → GlcA → GlcNDS3S,6S → IdoA2S → GlcNS6S. 
      Heparin enhances AT-III mediated inhibition of thrombin by two mechanisms. 
Binding of pentasaccharide sequence to AT-III induces an allosteric change in the 
conformation of AT-III, making it more reactive towards thrombin. If the heparin chain is 
sufficiently long, sequence distal to the pentasaccharide binding site interacts with 
exosite-II of thrombin, effectively bridging the two molecules and thereby increasing 
their effective concentrations. (see Figure 11) In combination, these two mechanisms 
enhance thrombin-ATIII reaction more than 1000 fold. The ternary complex of 
antithrombin-thrombin-heparin complex has been independently solved by two 
groups.86,87 
 
 
22 
 
 
Figure 11. Mechanism of heparin induced inhibition of thrombin by AT-III. (A) 
Pentasachharide sequence (ball and stick) of heparin binds to AT-III (cartoon 
representation) and induces allosteric unfolding of reactive centre loop (circled) making it 
more flexible. (B) Ternary complex of thrombin (cartoon representation colored pink)-
antithrombin(cartoon representation in multiple coloring)-heparin (ball and stick 
representation with 2Fo-Fc electron density contoured at 1σ shown in blue). PDB code: 
1TB6. This figure is taken form Reference 87. 
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Thermodynamic studies of thrombin-heparin interaction show that binding of 
heparin to thrombin is non-specific and depends on heparin chain length. High salt 
dependence of KD indicates that a major component contributing to the binding energy is 
ionic. The crystal structure of PPACK-thrombin bound to heparin (1XMN) is consistent 
with this hypothesis. The structure consists of two heparin octasaccharides, each 
sandwiched between two thrombin molecules. Both heparin sequences interact differently 
with each of the thrombin molecules (through exosite-II), but in both the cases, the 
heparin chain makes extensive contacts with one and fewer contacts with the other 
thrombin molecules, indicating that the latter interactions are just to compensate the 
residual charge. Exosite residues that interact with heparin are R93, H91, R101, R126, 
R165, H230, R233, W237 and K240.51 (see Figure 12 and 13) 
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Figure 12. Crystal structure of thrombin bound to heparin (PDB ID:1XMN). The 
thrombin monomer (monomer AB) making extensive contacts with heparin is shown by 
semitransparent electrostatic surface potential (red is negative and blue is positive). 
Heparin is shown in ball and stick representation.  
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Figure 13. Schematic representation of the two heparin chains interacting with two 
thrombin monomers (A) AB and GH and (B) CD and EF respectively in the crystal 
structure of thrombin bound to heparin (PDB ID:1XMN). Ionic interactions are indicated 
by solid lines, dashed lines indicate hydrogen bonds, solvent mediated hydrogen bonds 
are shown by dotted-dashed line and jagged dotted line indicates potential ionic 
interaction for incompletely built side-chains. This figure was taken from Reference 51. 
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1.5.2 Sucrose Octasulfate: A Heparin Mimic? 
 
Figure 14. Structure of sucrose octasulfate. 
 
Sucrose octasulfate (see Figure 14) has long been considered to be a heparin 
mimic, in that it can dimerize Fibroblast growth factors (FGFs) in a manner similar to 
heparin.88-91 It has also been reported to bind and activate HC-II to a small degree.92
1.6 Interactions at the Na
 
However it has not been rigorously demonstrated to mimic heparins anticoagulant 
properties. 
+
The discovery that thrombin is a monovalent cation-activated enzyme was first 
reported by Orthner et. al. in a seminal paper of 1980.
 Binding Site 
93  The study showed that Na+ and 
other monovalent cations like K+ and Rb+, but not NH4+ or Li+ increased the efficiency of 
cleavage (kcat/Km) of several chromogenic substrates by ~ 10 fold. The study also 
showed a Na+ dependent decrease in the clotting time. The binding constant for thrombin 
was found to be 20mM at 30 ⁰C. The binding o f Na+ lead to a change in UV absorbance 
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difference spectra in the absorption range of Tyr residues. This was inferred to be due to 
a change in conformation of thrombin on Na+ binding. The subsequent three decades of 
research on this topic has led to a tremendous amount of information to explain the role 
of Na+
 The exact location of Na
 as an allosteric effector of thrombin. Most of the information is derived by 
exploiting three techniques: kinetics, mutagenesis and crystallography, and quite often, 
the inferences drawn from these studies are conflicting. 
+ binding remained elusive until much after the 
discovery of the role of Na+ as an allosteric effector inspite of several reported thrombin 
structures. This was due to the similarity in the observed electron density of Na+ ion and 
water. In 1992 Tulinsky et. al. crystallographically identified the Na+ binding site by 
exchanging Na+ with Rb+.55 Subsequently, Na+
Na
 was identified in several previously 
reported crystal structure where it was wrongly assigned to be an ordered water molecule. 
+ binding site is located in a narrow solvent filled cavity near Asp189 of the S1 
pocket. The cavity is 8 Å  18 Å in volume and is formed by four antiparallel β -strands 
between Cys182-Cys191 and Val213-Tyr228. The cavity extends from the active site to 
the opposite surface of thrombin. The Na+ ion is octahedrally coordinated with peptide 
carbonyl oxygen atoms of Arg221A and Lys224 and four conserved water molecules. 
This is further stabilized by interaction of the waters with side-chains of Asp189, Asp221 
and main chain atoms of Gly223 and Tyr184A. (see Figure 15) 
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Figure 15. Molecular environment of Na+ (yellow sphere) binding site in relation to S1 
specificity pocket. Thrombin is shown in cartoon representation (light blue). Important 
residues interacting with Na+
       
 are shown in stick representation. Water molecules are 
shown as red spheres. P1 Arg side-chain of PPACK is shown in stick representation 
(yellow). 
The effect of Na+ on the physiological substrates of thrombin shows an increase 
in rate of release of fibrinopeptide A and B, and cleavage of PARs. On the other hand, 
binding of Na+ decreases the specificity of thrombin for protein C activation. Since it was 
seen that binding of Na+ to thrombin generally increased the rate of hydrolysis of 
substrates the Na+ bound form was termed as “fast” form and the Na+ free form was 
termed as “slow” form. The relevance of the two thrombin forms to blood coagulation is 
 
 
29 
 
still a contentious issue as Na+ levels in blood are tightly regulated. Although, it has been 
reported that elevated and decreased levels of Na+ can lead to thrombosis and bleeding 
respectively. The temperature dependence of KD of Na+ shows that at physiological 
temperature and Na+ concentrations (143 mM) both slow and fast forms are equally 
populated.20
Apart from the change in UV absorbance difference spectrum reported by Orthner 
et. al., evidence of a global conformational change comes from circular dichroism 
studies, which show a loss of ellipticity in the far UV region, implying a change in 
packing of certain aromatic residues. Near UV CD spectra show evidence for change in 
local asymmetry of aromatic residues. The CD spectra of thrombin in absence and 
presence of Na
 
+ grossly overestimate the amount of secondary structure in thrombin, 
indicating the contribution of packing of aromatic side chains and disulphide bonds to the 
CD signal. It is likely instead, that binding of Na+ to thrombin causes a conformational 
change of aromatic residue side-chains (and disulphide linkages) in loop regions of 
thrombin. Evidence that Trp residues are involved comes from the reported ~20% 
increase in intrinsic fluorescence of thrombin upon Na+ binding.94, 95
Careful kinetic studies indicate that Na
 
+ binding increases the rate of association 
of substrate binding (k1) and also the rate of deacylation (kcat), which is the final step in 
the catalytic cycle. Form this study and from previous observations of a general trend for 
increase in Km upon Na+ binding, it was concluded that the conformational change 
induced upon Na+ binding must be large enough to cause a general widening of the active 
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site cleft which remains in that configuration throughout the catalytic cycle of the 
enzyme. This effect is even more accentuated for substrates or inhibitors having 
significant interaction with the aryl binding pocket. This is exemplified by Y3A mutant 
of N-terminal peptide of hirudin. The Tyr3 residue occupies the aryl binding pocket of 
the active site and the wild type peptide binds with 35 fold higher preference for the Na+ 
bound form of thrombin. This preference is reduced to 1.3 fold in the Y3A mutant. This 
suggests that Na+ binding especially leads to widening of the aryl binding pocket.96
Apart from its allosteric effect on the active site, Na
  
+ binding is linked to changes 
in the exosite-I as  well. It has been observed that binding of C-terminus peptide of 
hirudin to the exosite-I exhibit the same changes to the kinetics of chromogenic substrate 
cleavage as does Na+ binding. Thrombin bound with hirudin at exosite-I shows no further 
change in kinetic properties upon Na+ binding. On the other hand, activity of Na+ bound 
thrombin does not change upon hirudin binding. Furthermore, affinity of hirudin for the 
fast form of thrombin is higher than that for the slow form. All this evidence suggests an 
allosteric linkage between Na+ binding site and exosite-I. Various residues energetically 
linked to Na+ binding have been mapped by extensive mutagenesis studies. The domains 
linked to Na+ binding are clustered in the Na+ binding site, active site and exosite-I. This 
means that the conformational change linked to Na+ binding must occur at specific 
regions and do not affect the secondary structure and global tertiary structure, as 
supported by the interpretation of UV and CD spectra. Finally, the residues at sites other 
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than the above stated ones might be involved in the allosteric communication between the 
active site, Na+ binding site and exosite I.95, 97
The structural evidence of thrombin slow→fast allostery is complicated by 
several issues. Firstly, most of the previously published thrombin crystals were grown in 
solutions containing Na
 
+ as a part of the crystallization buffer. Secondly, irrespective of 
the presence or absence of Na+ at the Na+
 
 binding site, the reported structures were 
always in the fast form as most of the structures were crystallized with an active site or 
exosite-I ligand. This is because of the well known communication among the three sites 
and the fact that binding of these ligands mimic the conformation of the fast form. 
Finally, crystal contacts themselves make a free energy contribution of ~3-6 kcal/mol, 
which is significantly higher than the energy difference between the two forms, implying 
that crystal contacts can mask any conformational changes due to slow → fast allostery. 
Recently, several crystal structures of the slow form of wild-type or mutant thrombins 
have been published. By comparing the main chain RMSDs (Cα RMSD) of these 
structures with the PPACK thrombin structure published by Bode et. al. (PDB ID: 1PPB) 
two classes of structures emerge: a) Class I structures with Cα RMSDs comparable to the 
RMSDs of other published fast forms of thrombin ( ~0.4 ) and b) Class II structures with 
3 fold higher Cα RMSDs compared to other published fast forms of thrombin (~1.25). 
(See Table 2) If we consider the average Cα RMSDs of all the fast forms (~0.4) as noise 
then the ratio of average Cα RMSDs of each residue of all the class I and  
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Table 2. Fast and slow structures submitted in the PDB and their respective Cα RMSD as 
compared to 1PPB 
Structure PDB ID Details Cα RMSD vs. 1PPB 
Fast forms 
1PPB 
1HAH 
 
1HXF 
 
1SG8_B 
1SG8_E 
 
1.9 Å, PPACK inhibited 
2.3 Å, Na+ and hirugen 
bound 
2.1 Å, Hirugen bound, Na+ 
free 
2.3 Å, Na+ bound, R77aA 
2.3 Å, Na+ bound, R77aA 
 
- 
0.35 
 
0.37 
 
0.40 
0.45 
Putative slow forms 
Class I 
1SGI_B 
 
1SGI_E 
Class II 
2AFQ_B 
2GP9 
1RD3_B 
1RD3_D 
 
 
2.3 Å, Na+ free from of 
1SG8 
2.3 Å, Na+ free form of 
1SG8 
1.9 Å , Na+ free, wild type 
1.9 Å, Salt-free, D102N 
2.5 Å, E217K 
2.5 Å, E217K 
 
 
0.40 
 
0.37 
 
1.30 
1.27 
1.25 
1.21 
 
class II slow forms and average Cα RMSDs for each residue of all the fast forms 
of thrombin will give us a per residue Signal:Noise for all Cα RMSDs compared to the 
1PPB control. This analysis shows that the class II structures show significant change in 
conformation which can be attributed to the slow form of thrombin. The class I structures 
 
 
33 
 
are conformationally indistinguishable from the Na+ bound fast form. A close analysis of 
residues undergoing major conformational change reveals a positive correlation between 
residues with high conformational change and their implication of being involved in 
slow→fast allostery from kinetic and mutagenesis data.  To no surprise, these residues 
are in the Na+ binding site, active-site and exosite-I, strongly reinforcing the hypothesis 
of allosteric communication between the three sites.98
It is very difficult to identify which among the class II structures is cognate to the 
actual in-solution slow form, but inferences can be drawn from the structural 
commonalities among these structures. All these structures show the Na
 
+ binding loop 
shifts more towards the active site cleft. This blocks the S1 pocket in all the structures. 
Another feature is the reorganization of the aryl-binding pocket. In 1GP9 Trp215 is in a 
conformation which would block P2 and P4 interactions, whereas in 1RD3, Trp215 
protrudes slightly into the S4 pocket. Finally, all the class II structures exhibit the 
destruction of the oxy-anion hole. The flipping of Gly193 leading to flipping of Glu192 
results in a non-catalytic hydrogen bond with Ser195. All these observations explain the 
biochemical data of substrates and inhibitors, especially the effect on S1 and aryl binding 
site widening upon Na+
A corollary to the comparison between the slow and fast structures is the 
observation that the residues involved in the conformational change are not disordered 
but are stabilized by extensive but different hydrogen bonding interactions. It can be 
 binding. The class II structures thus represent the slow form of 
thrombin.  
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inferred from this that the two forms represent energetic minima in solution. The 
observation of presence of catalytic activity even in absence of Na+ leads to the 
hypothesis that there is a rapid and dynamic equilibrium between the catalytically 
inactive and active forms of thrombin and the role of Na+ binding is to stabilize the active 
form. The evidence for this came from experiments by Shafer et. al.71 which studies 
change of intrinsic fluorescence upon Na+ binding. It was observed that the binding 
profile was biphasic, with the fast phase within the dead time of the stop flow device and 
the slow phase of ~30 s-1 which is independent of Na+ concentrations. The rate constant 
of the slow phase was found to be dependent on temperature. At higher temperature the 
binding profile is still biphasic but the ratio of fast:slow phase is similar to that obtained 
at 5 ⁰C. The data fits the model of thrombin in two forms: one capable of Na+ binding 
and the other incapable of Na+ binding, the transitioning from the later to the former 
accounting for the temperature dependent slow phase. Gianni et. al. resolved a linear 
dependence of the fast phase on Na+ concentration, implying that the conformational 
change reported by Shafer et. al. precedes Na+ binding.99
E* ↔ E ↔ E:Na
 The mechanism can be 
described by the following equation: 
Where E* is the thrombin conformer incapable of Na
+ 
+ binding and E is the conformer 
capable of Na+ binding. This rationalizes the observed differences (and similarities) in 
fast, slow(class I) and slow(class II) structures to be attributed to each of these forms can 
be assigned to E:Na+, E and E*  allosteric states, respectively. Gianni et. al. show that the 
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ratio of E*:E is 1:1 in absence of Na+  and Na+ is simply acting to stabilize the E state.99 
These recent findings have also led to a re-thinking of the “slow-fast” nomenclature 
because E state, although it has no Na+
1.7 Sulfated Dehydropolymers: Novel Allosteric Inhibitors of Thrombin Acting via 
Exosite-II 
 coordinated, is still catalytically active.  
In the last five decades, heparins and Vitamin K epoxide reductase inhibitors have 
been the mainstay for anticoagulant therapy. These anticoagulants suffer several 
limitations. This anticoagulants inhibit thrombin activity by enhancing its inactivation by 
ATIII (see section 1.5.1) or inhibiting thrombin biosynthesis. Vitamin K epoxide 
reductase inhibitors like warfarin suffer from several limitations like drug-drug 
interactions, drug-food interactions and high dose-response variability. Heparins on the 
other hand are ineffective in inactivating clot-bound thrombin. Further, unfractionated 
heparin (UFH) dose-response is highly variable due to its binding to plasma proteins. 
Because of the key role of thrombin in procoagulant pathways, direct thrombin inhibitors 
have recently received a lot of attention. Currently, only three DTI are approved by FDA 
viz. hirudin and its synthetic congener bivalirudin, and argatroban. In an effort to design 
new synthetic anticoagulants exploiting the template mechanism of heparin-induced 
thrombin inhibition, our laboratory discovered dehydro-polymers which display very 
interesting anticoagulant profile. 
Dehydro-polymers are heterogeneous and polydisperse polymers of cinnamic 
acids which were synthesized by a two step chemo-enzymatic means in a two step 
protocol. In the first step coupling of cinnamic acid monomers is done using enzyme 
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horseradish peroxidase (HRP). Three cinnamic acid derivatives were chosen for 
homopolymerization viz. caffeic acid, ferulic acid and sinapic acid. Upon action of HRP, 
various radical intermediates form, that further undergoes chain extension. Key among 
these linkages are β-O-4 and β-O-5 linkage (although, β-β, 5-5 and 5-O-4 linkages are 
also a possibility). In the second step, the polymers are sulfated using trialkyl amine-
sulfur trioxide complex. The resulting product is a heterogeneous and polydisperse 
mixture of sulfated dehydro-polymers of caffeic acid (CDs), ferulic acid (FDs) and 
sinapic acid (SDs) depending on the starting material used. (see Figure 16)  
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) 
measurement in presence of each of the DHPs indicated that they are potent 
anticoagulants. The DHPs were found to be 1.4 to 3.4 times more effective in prolonging 
PT, but 2.2 to 3.8 times less effective in prolonging aPTT, as compared to LMWH, with 
an overall higher effectiveness to prolong PT than aPTT. This implies that DHPs act on 
the intrinsic pathway more than on extrinsic pathway. 
  37 
Among the DHPs, the anticoagulant potency follows the order: CDs>FDs>SDs. It is 
possible that there is a positive correlation between the degree of structural diversity and 
anticoagulant potency, CDs being the most diverse and SDs being least diverse.100, 101
Interestingly, direct and indirect enzyme inhibition studies revealed that the major 
mechanism of coagulation is a selective inhibition of thrombin and fXa. This was a 
surprise as these compounds were designed to mimic the template mechanism of ATIII 
mediated thrombin inhibition similar to heparins. FDs, CDs and SDs showed nM IC
  
50 
values for both thrombin and fXa in absence of ATIII. (see Figure 17 and Table 3) 
Competitive inhibition studies for thrombin with heparins and C-terminal hirudin based 
peptide showed that CDs showed higher competition with heparins as compared to hirudin 
based peptide. This means that CDs have a preferentially bind to the exosite-II. Steady 
state kinetic studies with different concentrations of CDs showed that the Vmax (and kcat) 
decreased and the Km increased slightly when the CDs concentration was increased. It was 
hypothesized based on this that CDs cause an allosteric disruption of catalytic triad.102
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Figure 16. Chemoenzymatic synthesis of DHPs. CA, FA and SA stands for Caffeic acid, 
Ferulic acid and Synnapic acid respectively. This figure was taken from Reference 100. 
 
 
39 
 
 
Figure 17. Direct inhibition of fXa and Thrombin by CDs (solid triagles), FDs (square) 
and CDs (solid dots). This figure was taken from Reference 102. 
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Table 3. IC50 values of  inhibition of  Thrombin, fXa, fIXa and fVIIa by various DHPs in 
presence (direct) and absence (Indirect) of Antithrombin-III. This table was taken from 
Reference 102. 
 
 
The structural basis for this mechanism remains to be found in order to gain a better 
understanding of this novel mechanism. One of the problems in doing this is the 
heterogeneity inherent in the DHPs. To resolve this problem the lab recently synthesized 
small molecules that represent the scaffold of one of the possible monomeric unit which 
could comprise the putative DHPs structure. The compounds showed inhibition of 
thrombin and fXa, with 4AS (see Figure 18) being the most active. 
 
 
 
Figure 18. Structure of 4AS. 
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1.8 Specific Aims of the Research 
A) To Understand the Structural Basis of DHP Inhibition Using X-ray 
Crystallography: Since 4AS represents one of the monomeric unit of DHPs, it is a good 
starting point for initiating structure-based drug design. Our aim is to solve the structure of 
4AS complexed with thrombin. The minimum information that could be derived from the 
study is the location of binding site of 4AS on thrombin. Careful comparison of crystal 
structure of native enzyme and its isomorphous soaks may reveal the structural changes 
induced by the binding. 
B) To Characterize Thrombin-Sucrose octasulfate Interaction by Biophysical and 
Biochemical Methods: Thrombin-heparin interaction has been extensively studied by 
fluorescence spectroscopy using active site fluorescent probe p-amino benzamidine. We 
propose to use the same method to characterize thrombin-SOS interaction. SOS and 
heparin have a sulfated sugar scaffold. Unlike heparin, sucrose octasulfate has higher 
charge density. The effect of sugar chain length has been characterized using different 
chain length heparins. We would like to determine the effect of charge density by studying 
this interaction. 
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CHAPTER 2 CRYSTALLOGRAPHIC ANALYSIS OF 4AS-SOAKED 
NATIVE BOVINE THROMBIN CRYSTALS AND HUMAN PPACK 
THROMBIN- 4AS CO-CRYSTALS  
 
 
2.1 Introduction 
2.1.1 Overview of Drug-Protein Crystallography 
Protein crystallography is a biophysical method used to generate accurate models 
of proteins at atomic or near-atomic resolution. The wavelength of x-rays falls in the range 
(~1.5 Å) appropriate to deduce information about inter-atomic distances from diffraction 
scattering through interaction of the x-rays with the electrons of atoms.  The method 
involves passing of an x-ray beam through a high quality protein crystal of appropriate 
size, and recording the diffraction pattern on an image plate or detector. By accurately 
measuring the position and intensity of each spot on the diffraction pattern, it is possible 
(with supplemental phase information) to construct a 3D map of electron density of the 
repeat unit of the crystal (the unit cell). Once the electron density map is generated, it is 
possible to build an accurate model of the molecule into this density. 
The requirement of good quality protein crystals arises for two reasons: firstly, 
single molecules give weak diffraction, and secondly, in solution molecules are in constant 
motion which leads to a cancelling out diffracted x-rays. The repeated and periodic 
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arrangement of atoms in a crystal enhances the signal of each diffracted x-ray so that it is 
possible to measure its intensity with high statistical confidence levels. 
Drug-protein crystallography adds an additional step in protein crystallography, in 
that, at some point during the experiment the drug needs to be incorporated, which can be 
done by adding appropriate concentrations of the drug in the crystallization buffer. This 
method is called co-crystallization. Alternatively, a preformed native protein crystal can be 
soaked in a solution that contains the drug. Unlike small molecule crystals, protein crystals 
contain between 40 to 70 % solvent. If given enough time, the drug can diffuse through the 
solvent channels and get incorporated into the crystal.103, 104
Drug-protein crystallography aids immensely to the process of structure-based drug 
discovery. It gives atomic level information about interactions made by the drug with the 
protein. Additionally, by comparing the structural differences in the drug-bound and 
unbound crystal forms it is possible to understand the structural basis of drug action. The 
information derived from the experiment can be further used to make modifications in the 
lead structure. It is also possible to use the information in virtual screening and docking 
studies of homologous series of compounds.
 
105
2.1.2 Rationale for Specific Aim A 
 
Since DHPs interact with thrombin at or near exosite-II it can be hypothesized that 
4AS also would interact with that region. Since 4AS contains a sulfate and a carboxylate, it 
is likely that a sizable contribution to the binding energy would be ionic in nature. To 
avoid ionic screening effects, which could interfere in binding, it is necessary to screen for 
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crystallizing conditions having low ionic strength. In order to identify the allosteric 
changes induced by 4AS binding to thrombin, a native thrombin crystal has to be 
crystallized for comparison. Solving the structure of 4AS soaks of native thrombin crystal 
and comparing it with the native structure would unambiguously delineate the changes 
induced by 4AS binding. If the structural changes are small and the difference between the 
solution-form free energies of bound and unbound states are low, it is possible that the 
changes could be masked due to stabilizing crystal contacts in a pre-formed crystal. It is 
therefore also desirable to find a co-crystallizing condition for 4AS-thrombin complex.  
It was surprising to find that among the ~550 thrombin structures deposited in the 
PDB not a single structure was that of unliganded wild-type thrombin (in fast form). Most 
of the information on thrombin structure has been derived from PPACK-thrombin and 
hirugen-thrombin structures. Recently, Iyaguchi. et. al. reported preliminary crystallization 
data of unliganded wild-type bovine thrombin.106
 
 But, the group has not reported the 
solved structure. It was proposed that these conditions be used for obtaining crystals for 
subsequent soaking. Both the native and derivative structure would be solved and 
compared. At the same time, small scale crystal trials to find co-crystallization conditions 
of thrombin-4AS complex were also proposed. 
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2.2  Results 
2.2.1 Crystallization of Native Bovine thrombin and Human PPACK thrombin under 
co-crystallization conditions with 4-AS 
The crystals of native bovine thrombin obtained under the reported conditions were 
of suboptimum size and unsuitable for diffraction experiments. (see Figure 19) This 
necessitated further screening and optimization of these conditions. As seen in the Figure 
19, under the reported conditions, there was significant protein precipitation and also a 
high degree of nucleation. This leads to depletion of protein from the mother liquor by 
protein precipitates and simultaneously growing crystal nuclei, and as a result, the crystals 
fail to grow to larger dimensions. The goal of optimization was to achieve optimum size by 
decreasing the nucleation and precipitation. This was done by a carefully changing each 
condition variable, adding various additives and changing the experimental set-up (sitting-
drop, micro-dialysis etc.) The crystals obtained after optimization are shown in Figure 20. 
The results of the optimization trials are summarized in Table 4.  
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Table 4. Result summary of optimization trials for native bovine thrombin crystals. 
Condition Variable Observation 
PEG  PEG 3350 gave large crystals without any 
associated precipitates. Optimum 
concentration was 20 % w/v. Crystal 
formation under these conditions was 
so rapid that crystals could be seen 
immediately after the cover-slip was 
placed over the reservoir!  
2-Propanol  Change in concentration did not affect the 
amount of nucleation considerably  
pH  Optimum pH was 6.2 ± 0.2, pH lower than 
5.8 lead to precipitation  
Buffer concentration  Low concentrations of sodium citrate gave 
precipitates  
Buffer substitution  MES, PIPES, Cacodylate and Bis-tris were 
used at pH 6.2 instead of sodium 
citrate. No crystals formed in any 
except in PIPES  
Protein concentration  Optimum concentration was between 4.5 to 
6.5 mg/ml  
Drop Size  Larger drops gave larger crystals  
Crystallization method 
      Sitting drop 
      Sandwich drop 
      Micro-dialysis  
Large amount of nucleation 
Same as hanging drop 
Large amount of nucleation  
Other adjuvants  
    Calcium 1mM, 5 mM  
    Glycerol 3, 5,10 % v/v  
Does not considerably affect the crystal 
size 
Increasing concentrations of glycerol gave 
decreasing amounts of nucleation  
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Figure 19. Crystals of native bovine thrombin under previously reported conditions.106 
 
Figure 20. Crystals of native bovine thrombin obtained under optimized conditions.  
~0.075mm 
~0.075mm 
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Figure 21. Human PPACK thrombin grown from crystallization buffer containing 4-AS. 
Each graduation is approximately equal to 0.05 mm. 
 
Bovine thrombin crystals were grown under conditions where there was possibility of 
autolytic degradation. Since the crystals grew fairly quickly, autolytic degradation was not 
anticipated. This was confirmed with SDS-polyacrylamide gel electrophoresis under 
reducing conditions of the crystals which showed no signs of degradation. (see Figure 22) 
. In order to screen co-crystallization conditions for thrombin-4AS complex, human 
thrombin was covalently inhibited with PPACK. One such condition gave very large 
crystals. (Human ppack thrombin form-I) Although these crystals showed signs of 
epitaxial twinning at certain portions (see Figure 21), it was possible to perform the 
diffraction experiment by using parts of the crystal which seemed to have grown from a 
single nucleus. 
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Figure 22. SDS polyacrylamide gel of native bovine thrombin crystals of different age and 
the corresponding mother liquor solution in which they were grown. 
 
2.2.2  X-ray Diffraction Experiments 
Complete data-sets of native bovine thrombin, bovine thrombin-4AS soaks and 
human ppack thrombin crystal form-I were collected for several crystals, out of which the 
best data was chosen for further analysis. Analysis of the systematic absences showed that 
the native bovine thrombin crystals and its 4AS derivatives belong to space-group P43212 
or P41212 with unit cell parameters a = b = 87.64 Å, c = 194.51 Å; α = β = γ = 90⁰; and a = 
b = 87.64 Å, c = 195.99 Å; α = β = γ = 90 ⁰ respectively. The Rmerge of the native and the 
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derivative was calculated to be 16.7 % and 15.3 % respectively. Human ppack thrombin 
crystal form-I belonged to orthorhombic space-group P212121 having unit cell dimensions 
of a = 44.36 Å, b = 73.78 Å, c = 100.29 Å; α = β = γ = 9 0 ⁰. The Rmerge
Table 5. Preliminary diffraction data of native bovine thrombin, bovine thrombin-4AS 
soak and human ppack thrombin form-I. 
 was 17 %. 
Preliminary diffraction data for the three crystals is summarized in the Table 5. 
Parameter  Native bovine 
thrombin  
Bovine thrombin-
5AS soak  
Human-PPACK 
thrombin form-I 
Space group  P4
3
2
1
2 or P4121 P42 3212 or P4121 P22 12121  
Unit cell parameters  a=b=87.64 , 
c=194.51 
α=β=γ=90⁰  
a=b= 87.64, 
c=195.99 
α=β=γ=90⁰  
a= 44.36, b= 73.78,      
c =100.29   
α=β=γ=90⁰  
Resolution (Å)  39.20-2.8 (2.9-2.8) 40-2.5 (2.59-2.5)  38.02 –2.7 (2.80 -
2.70)  
Number of observed 
reflections  
69882  133569  40521  
Unique reflections  16696  27046  8843  
Completeness(%)  85.9 (97.7)  99.1 (99.9)  92.5 (98.6)  
R
merge
16.7 (30.8) (%)   15.3 (35.2)  17 (41.6)  
Cell Volume (cubic 
Å)  
1494137.3 1505275.75 328260.594  
 
2.2.3 Structure determination 
Models obtained from molecular replacement solution of native bovine thrombin, 
bovine thrombin-4AS soak and human PPACK thrombin crystal form-I, were refined to an 
R factor below 0.3. The refined model statistics for each structure, are given in Table 6. 
The Ramachandran plot for each of the structures is shown in Figures 23-25 . R factors 
and Ramachandran plot indicate that the models are consistent with the experimental data 
and allowed bonding geometries respectively. Moreover, examination of 2Fo-Fc map 
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shows that most of the density is accounted for by the model. A detailed examination of 
the electron density map revealed no density for ligand in both bovine thrombin-4AS soaks 
as well as human PPACK thrombin crystal form-I. 
 
Table 6. Refined model statistics for native bovine thrombin, bovine thrombin-4AS soak, 
and human PPACK thrombin crystal form-I structures. 
 Native bovine 
thrombin  
Bovine thrombin 
soaks  
Human PPACK 
thrombin 
R factor  0.23  0.24  0.27  
R free  0.29 0.30 0.37  
% reflections in test 
set  
10  10  5  
Bond length rmsd 
(Å)  
0.007  0.012  0.009  
Bond angles rmsd 
(deg)  
1.027  1.48  1.26  
Dihedral angles  
rmsd (deg.)  
18.367  19.27  21.16  
Planarity rmsd  0.004  0.006  0.006  
Chirality rmsd  0.075  0.092  0.084  
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Figure 23. Ramachandran plot of refined native bovine thrombin structure. Plot was 
generated using RAMPAGE.115 
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Figure 24. Ramachandran plot of refined bovine thrombin-4AS soak structure. Plot was 
generated using RAMPAGE.115 
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Figure 25. Ramachandran plot of  refined human PPACK thrombin form-I. The plot was 
generated using RAMPAGE.115  
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2.3 Experimental 
2.3.1 Crystallization of Native Bovine thrombin and Human PPACK thrombin-4AS 
co-crystals 
Bovine thrombin and human thrombin were purchased from Haematologic 
Technologies Inc. (Essex Junction, VT). They were supplied in vials containing 10mg/ml 
thrombin in 50 % v/v glycerol solution.  PPACK was purchased from BioMol Inc. Bovine 
thrombin was exchanged with 10 mM Tris-HCl, pH 8.0, and 50 mM NaCl using Amicon 
YM-10 ultracentrifugation tubes. The protein solution was stored in 10 μl aliquots at -80⁰C 
for future use. Human thrombin was diluted to 1 mg/ml using 0.2 M Phosphate buffer, pH 
6.5, and incubated with a 10-fold molar excess of PPACK for 20 min at 20 ⁰C. The 
solution was then exchanged with 2 mM MOPS buffer, pH 7, 0.1 M NaCl and 0.05 % w/v 
NaN3
Initial crystals of native bovine thrombin were obtained using the conditions 
reported by Iyaguchi et. al. by hanging drop vapor diffusion using 3 μl reservoir and 3 μl 
protein solution. The reservoir solution consisted 500 μl  of 0.1 M sodium citrate, pH 5.6, 
15 % w/v PEG 4000 and 20 % w/v 2-propanol. Tetragonal-bipyramidal crystals of 
dimensions 0.05 mm x 0.05 mm x 0.05 mm were obtained in two days at 25 ⁰C. 
. The solution was concentrated to 10 mg/ml concentration and stored at 4 ⁰C. 
Optimization of this condition was done by changing various parameters as listed 
in Table 7. Apart from the conditions listed in the table, crystallization was also tried with 
different crystallization methods like sitting-drop, sandwich drop and micro-dialysis and 
different pH conditions (5.5 to 7.0). Optimized crystals of 0.125 x 0.125 x 0.125 mm size  
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Table 7. Different conditions used to optimize the crystallization of native bovine 
thrombin crystals. pH under all conditions was 6.2. 
Condition 
# 
[Sodium Citrate] 
(M) 
[2-Propanol] 
(v/v) 
[PEG 3350] 
(w/v) 
Other additive 
1. 0.1 5 20 - 
2. 0.1 10 20 - 
3. 0.1 15 20 - 
4. 0.1 20 20 - 
5. 0.1 25 20 - 
6. 0.1 15 19.5 - 
7. 0.1 15 20.5 - 
8. 0.1 15 20 5 mM CaCl2 
9. 0.1 15 20 1 mM CaCl2 
10. 0.1 15 20 3 % v/v Glycerol 
11. 0.1 15 20 5 % v/v Glycerol 
12. 0.1 15 20 10 % v/v Glycerol 
13. 0.05 15 20 - 
14. 0.1 15 20 3 % v/v MPD 
15. 0.1 15 20 5 % v/v MPD 
16. 0.1 - 20 10 % v/v MPD 
17. 0.1 - 20 15 % v/v MPD 
18. - 15 20 0.1 M MES 
19. - 15 20 0.1 M Cacodylate 
20. - 15 20 0.1 M PIPES 
 
were obtained by hanging-drop vapor diffusion using 3 μl reservoir and 3 μl protein 
solution in one and a half day at 25 ⁰C. The reservoir solution consisted of 500 μl of 0.1 M 
sodium citrate, pH 6.2, 20 % w/v PEG 3350 and 15 % v/v 2-propanol.       
Human PPACK thrombin crystal form-I, was obtained using hanging-drop vapor 
diffusion method. 3 μl of solution containing 5 mg/ml human PPACK thrombin incubated 
overnight with a 10 fold molar excess of 4AS was mixed with 3 μl of reservoir solution. 
Reservoir consisted of 500 μl of 0.1 M Tris-HCl, pH 8.5 and 25 % v/v t-butanol. Large 
crystals of 0.25 mm x 0.25 mm x 1.5 mm were obtained in a week at 20 ⁰C. 
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2.3.2  Data Collection 
Diffraction experiments were performed on Raxis IV (Rigaku Americas Co.) under 
cryo-cooling conditions at 100 K. Native bovine thrombin crystals grown as described in 
the previous section, were swiftly taken out from the mother liquor using a nylon loop and 
flash-frozen under a stream of liquid nitrogen on the goniometer head. The crystals did not 
require cryo-protection due to the presence of 2-propanol in the mother liquor, which acts 
as a cryo-protecting agent. Indexing of initial still frames indicated a tetragonal space 
group, which requires a minimum data of 45⁰. Since redundant data was desirable, the 
diffractometer was programmed to collect 0.5⁰ oscillation frames from φ angles 0⁰ to 180⁰ 
at 0.5⁰ intervals (360 frames) and an exposure time of 15 minutes and crystal-to-detector 
distance of 150 mm. Once the data collection was complete, the data was integrated using 
d*trek program under the CrystalClear software package (Rigaku Americas Co.). 
Complete data-sets were collected on several single crystals and the best data set was used 
for structure determination. 
In order to prepare 4AS derivatives of native crystals, three hanging drops 
containing increasing concentrations of 4AS (with the highest concentration of 5mM 4AS) 
in the mother liquor were equilibrated against a reservoir solution for a day. The next day, 
native bovine thrombin crystals which were previously grown were consecutively 
transferred into the pre-equilibrated drops containing increasing concentrations of 4AS. 
The crystals were soaked in each drop for 2 hours. After the third soaking step, the crystals 
were mounted on the goniometer head as described for native bovine thrombin crystals. 
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0.5⁰ oscillation frames were collected from φ angles 0 to 180⁰ at intervals of 0.5⁰ and 
exposure time of 10 minutes and crystal-to-detector distance of 150 mm. The data was 
integrated, scaled and merged using d*trek. Two data sets were collected using single 
crystals, the best of which was used for structure determination. 
Initial diffraction experiments on Human PPACK thrombin crystal form-I showed 
that the crystals required cryo-protection. Cryo-protection was achieved by fast, 
consecutive transfers of the crystal in increasing concentrations of glycerol (10 % v/v, 15 
% v/v, 20 % v/v) in mother liquor, using a nylon loop, after which the crystal was 
immediately mounted on goniometer head. 0.5⁰ oscillation frames from 0⁰ to 180⁰ were 
collected using exposure time of 5 minutes and crystal to detector distance of 110 mm. The 
data was integrated, scaled and merged using d*trek. Several data sets were collected. 
Some of the crystals showed overlapping diffraction patterns indicating cracking of crystal 
or presence of epitaxial twinning. The best data-set was used for determining the structure. 
The data collection protocols for native bovine crystals, its 4AS derivatives and human 
PPACK thrombin crystal form-I are summarized in Table 8. 
Merged reflections from d*trek are in the form of intensities. The intensities were 
converted to amplitudes using TRUNCATE program in CCP4 program suite 6.1.0.107 In 
doing so, the program assumes negative intensities as zero and takes a square-root of the 
reflection intensities. Analysis of Matthew’s coefficient probabilities108 suggested two 
molecules of bovine thrombin per asymmetric unit and one molecule of human PPACK 
thrombin per asymmetric unit. 
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Table 8. Data collection protocol 
Parameter Native bovine 
thrombin  
Bovine thrombin-
4AS soaks  
Human PPACK 
thrombin form-
I 
Cryo-protecting 
conditions 
Not required  Not required  To 20 % 
glycerol in steps  
Soaking conditions -  5 mM β-5MSC in 
mother liquor  
Crystal grown in 
1 mM β-5MSC  
Crystal to detector 
distance  
150 mm  150 mm  110 mm  
Exposure time  15 min  10 min  5 min  
Start and end angle  0⁰ – 180⁰  0⁰ – 180⁰  0⁰ - 180⁰  
    
 
2.3.3  Structure determination 
An automated molecular replacement (MR) search was done using PHASER 2.1 in 
the molecular replacement module of CCP4. The coordinates of L and H chains of 1MKX 
were used as a search model for native bovine thrombin and 4AS soak. Single solutions 
were obtained for space group P4321
Previously solved structure of human PPACK thrombin (PDB ID: 1PPB) was used 
as a search model for MR for human PPACK thrombin from-I. Single solution was found 
in P2
2 for native bovine thrombin and its 4AS derivative. 
High log likelihood gains (LLG) and translation function Z-scores (TFZ) indicated that the 
solution found were correct.  
12121
 
 space group. The summary of phasing by molecular replacement is shown in 
Table 9.  
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Table 9. Molecular replacement summary. 
 Native bovine 
thrombin  
Bovine thrombin-
5AS soaks  
Human PPACK 
thrombin form-I 
Search model 
(PDB ID)  
1MKX   1MKX  1PPB  
Sequence identity  100%  100 %  100 %  
Nmol/assymetric 
unit  
2  2  1  
RF Z  11.3  14.6  19.9  
TFZ  50.3 19.5 33.7  
LLG  2035  2034  1245  
 
In order to remove phase bias from the models obtained from molecular 
replacement, initial cycle of refinement was done using simulated annealing in Phenix 1.4-
3109
The models obtained from simulated annealing were examined in Coot 0.5.2 
against weighted 2F
. For human PPACK thrombin structure, simulated annealing in CNS 1.2 was used 
rather than phenix. This was because the human PPACK thrombin data is of relatively low 
resolution. At low resolution there is a higher parameter:observables ratio which can lead 
to over-refinement. Phenix.refine uses a cartesian coordinate refinement. This has higher 
number of refinement parameters, increasing the possibility of over-fitting at low 
resolution, as the number of observables is low relative to the parameters being refined. 
o-Fc (at 1σ contour level) and Fo-Fc (at 3σ contour level) difference 
maps.110 The model was manually fit to 2Fo-Fc density using utilities in Coot. This was 
followed by a restrained refinement in REFMAC 5.5. This cycle of manual fitting followed 
by restrained refinement was repeated until no further improvement in the model was 
observed. To guide this process the R and Rfree were monitored throughout the process. 
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2.4 Discussion 
Reasons for the absence of density to account for 4AS were investigated. One 
possible reason could be that the affinity of ligand is diminished in the crystallization 
buffer. But, since the two structures that were solved, were from crystal forms grown in 
significantly different buffer, pH and ionic strengths; the chances of this being the case is 
low and could point to a general low affinity of 4AS towards thrombin. The affinity of 
4AS could not be determined using the fluorescent probe para amino-benzamidine due to a 
high amount of interference from 4AS. From the fluorescence experiments, it was also 
observed that 4AS did not give any change in fluorescence emission in presence or absence 
of thrombin. This precluded the determination of 4AS affinity using reverse titrations. 
     Another possibility could be that the crystallographic contacts might be blocking the 
binding site of 4AS. Examining the packing arrangement of the asymmetric unit and its 
neighboring symmetry related molecules, in both the structures, revealed a fully free and 
solvent exposed exosite-II. (see Figure 26) It is possible; however, that 4AS binds to a site 
other than exosite-II which might be unavailable for binding. 
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Figure 26. Asymmetric unit of bovine thrombin-4AS soak structure (green) shown along 
with neighboring symmetry related molecules (grey). The white circle shows unhindered, 
solvent-exposed exosite-II region. 
  
If the occupancy of the 4AS is low, complete density may not show up. This could 
especially become problematic in the case where model has large difference between R 
and Rfree, as in the case of the PPACK thrombin form-I. The quality of this model was 
determined by examining 2Fo-Fc
It was recently found (after the determination of both the crystal structures) that 
4AS inhibited the hydrolysis of chromogenic substrate by thrombin very weakly (~20% 
 omit maps contoured at 1σ. Omit maps showed good 
density for all parts of the model (see Figure 27), except for the 149-loop which was 
disordered. 
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inhibition of thrombin hydrolysis of chromogenic substrate spectrozyme-TH) at milli 
molar concentrations.111 This suggests a weak binding affinity of the ligand towards 
thrombin and can explain its absence in the electron density map solved by 
crystallography. 
 
Figure 27. 2Fo-Fc
 
 omit map contoured at 1σ overlaid on FPR fragment in human PPACK 
thrombin crystal form-I. 
In the process of finding the structure of 4AS bound to thrombin, the crystal 
structure of unliganded native bovine thrombin was determined. The unliganded thrombin 
structure had not been previously reported due to the autolytic degradation of thrombin in 
the crystallization drop when stored for a long time. This did not happen under these 
conditions, possibly due to a rapid crystallization rate. Crystals attain maximum size within 
3 days. 
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Although the structure was solved at a low resolution, several important aspects of 
the structure could be determined. The structure showed strong density for sodium at the 
sodium binding site indicating that both monomers in the asymmetric unit were sodium 
bound. Cα superposition of residues of the refined model on L and H chains of 1MKX 
shows an identical topology. (see Figure 28) Superposition of the active site catalytic triad 
is shown in Figure 29. 
 
Figure 28. Overlay of protein backbone of bovine thrombin from 1MKX and solved 
structure 
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Figure 29. The catalytic triad of L and H chain of 1MKX (blue) superposed on the solved 
native bovine thrombin structure (green). 
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CHAPTER 3 BIOPHYSICAL AND BIOCHEMICAL CHARACTERIZATION OF 
THROMBIN-SUCROSE OCTASULFATE INTERACTION  
 
 
3.1 Rationale for Specific Aim B 
Thrombin-heparin interaction has been previously characterized by monitoring the 
change in fluorescence intensity of the active site fluorescent probe para-amino 
benzamidine (PABA). Sucrose octasulfate (SOS) has a sulfated sugar scaffold and would 
be expected to interact with thrombin in a manner similar to heparin. We propose to find 
the equilibrium dissociation constant of SOS using the fluorescent probe PABA. By 
determining the dissociation constant of SOS at different salt concentrations, it is possible 
to determine the ionic contribution to binding energy. By comparing the salt dependence of 
SOS-thrombin and heparin-thrombin interaction, which was previously reported,112
Since SOS has no physiologically relevant anticoagulant property, the binding of 
SOS to exosite-II can be exploited to compete with inhibitors binding to exosite-II, and 
therefore can be envisioned as an antidote for such inhibitors. To explore this potential, 
competitive enzyme-inhibition experiments with DHPs were designed. Also, combined 
with the competitive enzyme inhibition experiments, indirect inference of the approximate 
site of DHP binding can be deduced by solving a crystal structure of thrombin complexed 
 the 
effect of high charge density of SOS on interaction with exosite-II can be understood. 
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with SOS. Conditions used to determine native bovine thrombin structure (see section 2.3) 
can be used to obtain co-crystals of SOS complexed with thrombin. 
3.2 Determination of Equilibrium Dissociation Constant (KD
3.2.1 Results 
) and Salt Dependence 
for Thrombin-Sucrose Octasulfate Interaction 
Fluorescence equilibrium binding titration of SOS with thrombin-PABA complex 
showed a concentration dependent and saturable change (quenching) of thrombin-PABA 
fluorescence which could be fitted to a quadratic binding isotherm as shown in the 
equation below: 
 
where, ΔF/Fo is the fractional change in fluorescence emission as compared to initial 
fluorescence Fo where no ligand is present; [P]o is the protein concentration used; [L]o is 
the concentration of the ligand, SOS in this case; KDobs is the observed equilibrium 
dissociation constant and ΔFmax
           The binding isotherms for three different salt concentrations were fitted on the 
experimental data using Sigma-plot and are shown in Figures 30-32. The K
 is the maximal change in fluorescence emission. 
D value 
determined for each experiment is given in the Table 10.  
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Figure 30. Binding isotherm of sucrose octasulfate for thrombin at 50 mM NaCl. 
 
Figure 31. Binding isotherm of sucrose octasulfate for thrombin at 150 mM NaCl 
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Figure 32. Binding isotherm of sucrose octasulfate for thrombin at 250 mM NaCl. 
Table 10. KDobs
[NaCl] (M) 
 values of sucrose octasulfate-thrombin interaction at different salt 
concentrations. 
KDobs ΔF(μM) max 
0.05 1.4 ± 0.3 -0.048 ± 0.001 
0.15 22.1 ± 4.1 -0.064 ± 0.003 
0.25 148.1 ± 24.7 -0.092 ± 0.006 
 
3.2.2 Experimental 
Human thrombin was purchased from Haematologic Technologies (Essex Junction, 
VT) and used as such. Para-amino benzamidine and sodium sucrose octasulfate was 
purchased from Sigma-Aldrich and BIOMOL international (Plymouth Meeting, PA). 
 
 
70 
 
Fluorescence binding titrations were performed in 20 mM Phosphate buffer, 0.1 mM 
EDTA and 0.1 % PEG 8000 and three different concentrations of NaCl (0.05 M, 0.15 M, 
and 0.25 M). Acrylic cuvettes coated with PEG 20,000 were used for this purpose. The 
QM-4 configuration in spectrofluorimeter (PTI ltd.) was used and the experiments were 
carried out at a constant temperature of 25 ⁰C.  The excitation and emission wavelengths of 
345 nm and 370 nm respectively and excitation and emission band-pass of 4 nm and 8 nm 
respectively were selected for the experiments. Each reading was corrected for dilution and 
background fluorescence of PABA. 
3.3 Competitive Enzyme Inhibition Assays of DHPs in Presence of Sucrose 
Octasulfate 
 
3.3.1 Results 
IC50 values of FDs in presence of increasing concentrations of SOS were 
determined using chromogenic substrate Spectrozyme-TH. Semi-logarithmic plots were 
fitted to the equation given below: 
 
 
where, Y is the fractional residual proteinase activity in presence of inhibitor to its absence. 
YM and Yo are the maximum and minimum possible values of the fractional residual 
proteinase activity, IC50 is the concentration of inhibitor that leads to a 50 % inhibition of 
enzyme activity and HS is the Hill slope. 
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The fitted plots showed characteristic sigmoidal shape seen in a standard dose-
response curve. It was observed that the graph was shifted to the right as the concentration 
of SOS used in the experiment increased a characteristic behavior of competitive binding. 
(see Figure 33) However the extent to which the plot is shifted slowly diminishes as the 
concentration of SOS increases.  The IC50 values are listed in Table 11.  
 
Figure 33. Inhibition of thrombin by FDs in absence and presence of SOS. Each data point 
is represented by different shaped symbols as shown in the legend. The fit is shown by 
different colored smooth lines.  
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Table 11. IC50
[SOS] (μM) 
 values of FDs for thrombin in the presence of various concentrations of 
SOS. 
IC Y50 Yo HS M 
0 0.8 35.1 102.2 0.9 
50 1.8 47.2 98.7 0.9 
100 1.9 56.5 101.7 1.0 
200 2.7 45.2 99.9 0.9 
 
While measuring the residual thrombin activity of control which contained SOS but 
no DHPs, it was found that SOS itself inhibited thrombin, with the highest inhibition of  
~12% seen at 200 μM. To investigate this behavior further, enzyme inhibition assay similar 
to that used for FDs was performed. The experiment showed that SOS inhibited thrombin 
with an IC50 of 3.8 μM with maximal inhibition of 12.8 %. A semi-logarithmic plot fitted 
according to the equation given above is shown in Figure 34.  
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Figure 34. Inhibition of thrombin activity by SOS. Data points used to generate fit 
(smooth line) are shown by solid circles. 
 
3.3.2 Experimental 
Spectrozyme-TH was purchased from American Diagnostica (Greenwich, CT). 
FDs was synthesized in our lab by the protocol of Monien et. al.100 Competitive assays of 
inhibition of thrombin proteinase activity by FDs were done in presence of three different 
concentrations of SOS (50 μM, 100 μM and 200 μM). An assay where no SOS was present 
served as control. 15 stock solutions at concentrations from 0.12 μM to 4 mM FDs 
(concentration calculated using an average molecular weight of 4120 Da) were prepared. 
10 μl of each solution was added to 930 μl of phosphate buffer, pH 7.4, 0.1 mM EDTA, 
0.1 % v/v PEG 8000 and 0.15  M  NaCl in PEG 20,000 coated cuvettes to which 1 μl of 
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SOS stocks (which make appropriate final SOS concentration) was added. 10 μl of human 
thrombin (500 nM) was added to each cuvette and mixed. After 10 minutes of incubation, 
30 μl of 1 mM Spectrozyme-TH was added successively to each cuvette, rapidly mixed 
and the residual enzyme activity was determined by measuring the initial rate of increase in 
absorbance at 405 nM. Residual proteinase activity relative to negative control where no 
FDs or SOS was present was calculated for each concentration of FDs. IC50
 
 values for 
control, 50 μM SOS, 100 μM SOS and 200 μM SOS were measured by fitting the data 
from each of the respective experiment to the equation shown in section 3.4.1 
Enzyme inhibition assays for determining IC50 of SOS were performed using the 
same procedure used to determine the IC50
3.4 Crystal Structure Determination of Thrombin-Sucrose octasulfate Complex 
 of DHPs. Stock solutions containing different 
concentration of SOS ranging from 97 μM to 20 mM were used instead of FDs. 
3.4.1 Results 
The preliminary data for SOS-bovine thrombin co-crystal is shown in the Table 12. 
After successful molecular replacement the structure was refined to an R and Rfree
 
 value of 
0.23 and 0.28 respectively. The Ramachandran plot of the refined model is shown in 
Figure 35.  
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Table 12. Preliminary diffraction data of bovine thrombin-SOS co-crystals 
Parameter Native bovine thrombin 
Space group P4
3
2
1
2 
Unit cell parameters a=b=87.56 , c=191.99 
α=β=γ=90⁰ 
Resolution (Å) 27.92-2.2(2.28-2.2) 
Number of observed 
reflections 
304797 
Unique reflections 38745 
Completeness(%) 99.8 (100) 
R
merge
8.3 (31.1) (%) 
Cell Volume (cubic 
Å) 
1472000.543 
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Figure 35. Ramachandran plot of the refined structure of bovine thrombin-SOS co-
crystals. The plot was generated using RAMPAGE.115 
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Examining the 2Fo-Fc and Fo-Fc maps revealed clear density for Na+ and various 
ordered water molecules in and around the Na+ binding site. The two Na+ ions were put 
into the model. At the same time, waters showing clear density in the 2Fo-Fc map along 
with positive density in Fo-Fc and making at least one contact with the protein were also 
incorporated into the model. It was observed that there were two large blobs of density 
close to exosite-II showing up in both the 2Fo-Fc and Fo-Fc maps. SOS was built into both 
these regions of densities. The sulfate groups on SOS were fit first followed by the sugar 
ring. After refinement, the 2Fo-Fc map showed a good fit for both the SOS molecules. It 
should be noted that the density for SOS was weak and it was not possible to ascertain 
features like ring puckering and binding conformation for the two SOS molecules. In order 
to make sure that SOS was correctly fit, 2Fo-Fc
The two molecules of SOS (SRC1 and SRC2) interact with exosite-II of the two 
thrombin monomers (A and B) forming the asymmetric unit. SRC1 interacts with both the 
monomers, while SRC2 makes exclusive interactions with exosite-II of one of the 
monomers (A). (see Figure 37) Careful examination of electron density around the two 
SOS molecules shows that SCR2 makes an ionic hydrogen bond with His91(A) and 
electrostatic interaction with Lys236(A). Density for these interactions is also present in 
 omit maps, contoured at 1σ were 
generated. The omit maps showed only broken density for the two sucrose octasulfate 
molecules, with missing density on the sugar backbone. Interestingly, the density seen in 
the omit maps was in the region of SOS that interacts with the protein, indicating these 
regions to be more ordered.       
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the 2Fo-Fc omit maps. The residues within interacting distance of the two SOS molecules 
are Arg93(A), Lys101(A), Lys126(B), Lys235(B), Arg240(A) Lys240 (A) and Arg244(A). 
(see Figure 38) 
 
Figure 36. Interaction of two SOS molecules(SCR1 and SCR2) with two thrombin 
monomers (A and B) in the asymmetric unit. 2Fo-Fc map contoured at 1σ is shown for 
SCR1 and SCR2. 
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Figure 37. Thrombin residues in interaction distance of the two SOS molecules: SRC1 and 
SRC2 (shown in stick representation overlaid with 2Fo-Fc map contoured at 1 σ). The 
letter in parenthesis indicates the thrombin monomer to which each residue belongs. 
 
Examination of the difference maps showed that the occupancy of the SOS 
molecules was below 1. This could be due to weak or non-specific binding. Since it was 
possible that citrate ions, present in the buffer, which has a moderately high charge-density 
might be interfering with binding. An additional data-set was collected in which the citrate 
was exchanged with cationic buffer bis-tris. Preliminary data for this crystal is given in 
Table 13. The model obtained from this data also showed two large electron density blobs 
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at the same location as that found in the previous structure. This strongly increases the 
confidence in the SOS molecules fit in the previous structure.  
Table 13. Preliminary diffraction data for bovine thrombin-SOS co-crystals exchanged in 
bis-tris. 
Parameter  
Space group P4
3
2
1
2 
Unit cell parameters a=b=87.76 , c=190.62 
α=β=γ=90⁰ 
Resolution (Å) 39.86 – 2.3 (2.38 – 2.3) 
Number of observed 
reflections 
408377 
Unique reflections 33783 
Completeness(%) 99.5 (100) 
R
merge
15.5 (37.7) (%) 
 
3.4.2 Experimental 
Bovine thrombin obtained from Haematologic Technologies (Essex Junction, VT) 
and processed as described in section 2.3.1 was diluted to a concentration of 7 mg/ml using 
0.01 M Tris-HCl, pH 8.0, 0.05 M NaCl. It was incubated for an hour with 20 mM SOS and 
this solution containing 20mM SOS and 7 mg/ml thrombin was used for crystallization 
under the optimized condition described to crystallize native bovine thrombin. (see section 
3.2.1) Crystals of 0.5 mm x 0.5 mm x 0.5 mm dimensions grew at 25 ⁰C, from hanging 
drops, containing 4 μl of thrombin-SOS mixture and 4ul of reservoir. Reservoir was 
composed of ingredients listed in condition # 3 of Table in section 3.2.1. 
Frames from φ angles of 0 to 180⁰, at 0.5⁰ intervals, were collected from a single 
crystal which diffracted beyond 2.2 Å resolution. The data were integrated, scaled and 
merged using d*trek. Preliminary analysis of the data showed a space group of P43212 as 
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was the case with native bovine thrombin crystals. One of the unit cell dimensions (c) was 
considerably different as compared to native crystals and 4AS soaks. 
The reflection intensities were converted to amplitudes using TRUNCATE107 and 
the resulting file was used to perform molecular replacement using coordinates of 1MKX 
as search model, as described previously for native bovine thrombin crystals and 4AS 
derivatives. The search gave a single solution in P43212 space group and two molecules 
per asymmetric unit. The model generated from molecular replacement was initially 
refined by simulated annealing in phenix.refine. The structure was further refined by cycles 
of manual refinement in Coot 0.5.2110
Another dataset was collected on SOS-bovine thrombin co-crystal grown under 
condition # 9 (Table 7), but before data collection, the citrate buffer was replaced by 0.05 
M bis-tris (keeping all the other conditions including SOS concentration same) by gradual, 
step-wise exchange. The crystals diffracted to 2.4 Å resolution. The structure was solved 
and refined to an R factor and R
 using weighted difference maps and restrained 
refinement in REFMAC 5.2. 
free
3.5 Discussion 
 of 0.24 and 0.30 respectively as described above. 
SOS at salt concentration of 150 mM, which is close to the physiological 
concentration of NaCl, has a KD of ~ 22 μM. Comparing this with similar chain length 
heparin fragment shows that SOS interacts with far greater affinity than heparin. The 
closest heparin homolog in terms of chain length is a tetrasaccharide. Its KD is reported to 
be 71±6 μM.112 On an average there is 2 times higher charge density on SOS compared to 
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heparin which could be the reason for lower KD. It has been previously reported that the 
presence of negatively charged groups on the ligands enhances the binding of ligand with 
exosite-I and exosite-II. This is due to the presence of a net dipole on these sites. It is 
possible that higher charge density on SOS leads to a faster associate rates (kon
The interaction of polyanionic ligand with protein can be illustrated by the following 
equation: 
). Although 
this may not have strong implications in designing better heparinoid mimetics, it adds one 
more piece of information to the understanding of the nonspecific interaction mechanism 
of ligands with thrombin exosite-II. 
 
where P is the protein concentration, L is the polyanionic ligand concentration, Z the 
number of charged interactions made by the ligand with the protein, Ψ is the fraction of 
monovalent counterion bound per activator ionic charge that is released on protein binding 
and can be taken as 0.8. M+ is the monovalent cation released when L binds to P. The KD 
for such equilibrium can be described by the following equation: 
 =  
 
Rearranging this gives: 
 
logKD(obs) = logKD(Non-ionic) + ZΨlog[Na+
Plotting logK
] 
D(obs) vs Ψlog[Na+] gives a straight line with slope of Z and y-
intercept of logKD(Non-ionic). The above equation was used to determine the value of KD(Non-
ionic)  and Z (number of ionic interactions per number of ligand bound) for SOS interaction 
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with thrombin. Figure 38 shows the plot of logKDobs vs  Ψlog[NaCl] for 50 mM, 150 mM 
and 250 mM NaCl. Fitting a straight line through the data-points gave a slope of 3.54 and a 
Y-intercept of -2.045. (see Figure 38) This means that the thrombin-SOS interaction has 
approximately 3.54 charged interactions and a KD(Non-ionic) of 6.2 mM. 
 
Figure 38. Salt dependence plot of thrombin-SOS interaction. 
Competitive experiments with FDs described in section 3.4 can be quantitatively analyzed 
by the Dixon-Webb relationship given by the following equation:  
 
A true competitor would shift the log dose-response curve to the right by a magnitude 
depending on the KD and concentration of the competitor as described by this relationship. 
Using the KD determined in section 3.1 and the experimental IC50 values measured at 
different concentrations of SOS we can calculate IC50calc. Table 14 shows IC50calc
Ψlog[Na+] 
 values. 
A graphical representation of the representation of this is shown in Figure 39. Clearly SOS 
lo
g[
K
D
ob
s] 
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is not a true competitor of FDs. The heterogeneous nature of FDs and the fact that SOS 
itself inhibits thrombin, further complicates this analysis. 
Table 14.  Comparision of IC50measured and IC50calc
[SOS] μM 
. 
IC50 IC measured (μM) 50 calc (μM) 
0 0.8 0.8 
50 1.8 4.2 
100 1.9 10.5 
200 2.7 26.7 
 
 
Figure 39. Graph of IC50measured measured experimentally at different concentrations of 
SOS(blue) and IC50calc
 
 calculated using Dixon-Webb relationship. 
Determination of the structure of bovine thrombin complexed with sucrose 
octasulfate shows two SOS molecules bound to thrombin. The additional structure solved 
without citrate, which was thought to interfere in the binding also revealed density for SOS 
at the same site as that solved in the previous structure. It should be noted that the density 
observed in the absence of citrate was not more well-defined than that observed with  
 
 
85 
 
citrate suggesting that the binding is still weak and possibly has multiple binding 
orientations. 
Comparing the neighboring residues to the fitted SOS molecules, shows that SCR2 
interacts only with thrombin monomer A and SCR1 interacts with exosite-II of both 
thrombin monomers (A and B). However, the interacting surface of SCR1 with monomer 
B is small compared to monomer A. It is possible that the interaction with thrombin 
monomer B is an artifact of crystal packing. SCR2 interacts with monomer A in a similar 
mode to the interaction of  heparin octasaccharide with exosite-II. (see Figure 40) 
In order to correlate the inhibition of thrombin cleavage of chromogenic substrate 
(section 3.4) with the structure results,  the Cα residues of the refined structure was 
superposed on 1MKX. No significant difference was found except for the 149-loop. The 
149-loop has been reported to be disordered in various structures previously published. In 
the current structure it was also found to be disordered. For most of its residues, density 
was only observed for the protein back-bone. No differences were found when the active 
site residues (His57, Asp102, and Ser195) were superposed on the corresponding residues 
of 1MKX. 
It is possible that the conformational change may have been masked due to crystal 
packing in this crystal form. Many previously reported structures of thrombin bound to 
exosite ligands fail to show any conformational change, even when in-solution studies 
indicate an allosteric perturbation of structure.47, 76, 113 In a recently reported structure of 
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thrombin complexed with suramin which was shown to inhibit thrombin by binding to 
exosite-II, the thrombin molecule did not show any significant conformational change.85  
 
Figure 40. Interaction of sucrose octasulfate molecule SCR2 (stick representation) with 
thrombin monomer (semi-transparent electrostatic surface representation). Important 
thrombin residues are also shown in stick representation and are labeled. 
 
3.6 Conclusion and Significance of Work 
Refined structures of bovine thrombin-4AS soaks and human PPACK thrombin-
4AS co-crystals were solved. The structure did not show any density for the ligand. In the 
process a new crystal form of native bovine thrombin in unliganded state was solved. This 
crystal form can be used to study thrombin-ligand interactions, especially for ligands 
binding to exosite-II, since it is not involved in any crystallographic contacts.     
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KD of SOS for thrombin was determined using fluorescence spectroscopy with the 
secondary probe PABA. The KD was significantly lower than heparin fragment of 
comparable size. The salt dependence of KD revealed that a significant contribution to the 
binding energy is due to ionic forces. The number of charge interaction per molecule of 
SOS bound to thrombin was calculated to be 3.5. Competitive enzyme inhibition 
experiments of FDs using increasing concentrations of FDs were carried out. It was found 
that there was ~2-3 fold increase in the IC50
The crystal structure of bovine thrombin cocrystallized with SOS showed two 
molecules of SOS bound to the two thrombin molecules in the asymmetric unit via exosite-
II. One of the SOS molecules which was bound exclusively to one thrombin monomer 
showed interactions very similar to that made by heparin octasachharide. Key among the 
interactions are Lys236, His91, Arg93 and Arg101. Characterization of this interaction 
novel interaction mode of sucrose octasulfate adds to our current evidence of compounds 
binding to exosite-II like heparin, but unlike heparin showing direct inhibitory properties. 
 of FDs at the highest concentration of SOS 
used (200 μM). Based on the Dixon-Webb relationship it was found that SOS is not an 
ideal competitor for FDs. 
3.7 Future Direction 
Recent studies have shown that 4AS is a more effective inhibitor for fXa than for 
thrombin. Crystallographic analysis of 4AS bound to fXa could be pursued. The optimized 
conditions for obtaining bovine thrombin crystals can be exploited for future soaking or 
co-crystallization experiments with tighter binding compounds based on the DHPs 
 
 
88 
 
scaffold. Apart from crystallography, in order to gain a better understanding of the 
allosteric mechanism of DHPs, a chromogenic substrate library can be used to identify 
changes in substrate specificity induced by the DHPs. Such work has been extensively 
reported by Vindigni et. al.114  Since SOS was found to inhibit thrombin, steady state 
kinetic studies study could shed light on its mode of thrombin inhibition. 
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